TY - JOUR T1 - Cancer-associated thrombosis: the when, how and why JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0119-2018 VL - 28 IS - 151 SP - 180119 AU - Caio J. Fernandes AU - Luciana T. K. Morinaga AU - José L. Alves,  Jr AU - Marcela A. Castro AU - Daniela Calderaro AU - Carlos V. P. Jardim AU - Rogerio Souza Y1 - 2019/03/31 UR - http://err.ersjournals.com/content/28/151/180119.abstract N2 - Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.Cancer-associated thrombosis (CAT) presents peculiar features (risk factors and pathophysiology) that distinguish it from common VTE cases. Treatment of CAT requires a different approach, since the patients are more prone to recurrence and bleeding. http://ow.ly/j1Lu30nYmd5 ER -